ARROWHEAD PHARMACEUTICALS, INC. business relationships
Companies named in ARROWHEAD PHARMACEUTICALS, INC.’s 10-K filed 2025-11-25, and public companies whose annual reports name ARROWHEAD PHARMACEUTICALS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 19% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Layers: GLP-1 & obesity
Named in ARROWHEAD PHARMACEUTICALS, INC.’s annual report 18
“...ty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $ 410.0 million in cash to the Company in consideration for the Company's future royalty interest in olpasiran, a siRNA originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement.” SEC filing
“• Parkinson's disease - ARO-SNCA (out-licensed to Novartis)” SEC filing
“Under the Second Collaboration and License Agreement (the "Olpasiran Agreement"), Amgen received a worldwide, exclusive license to the Company's novel RNAi olpasiran (previously referred to as AMG” SEC filing
“Non-Exclusively Licensed Patent Rights from Roche” SEC filing
“The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023.” SEC filing
“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories.” SEC filing
“On August 29, 2025, the Company entered into an Exclusive License and Collaboration Agreement (the "Novartis Collaboration Agreement") with Novartis Pharma AG ("Novartis") for the co-development and commercialization of multiple preclinical programs in rare, genetic diseases.” SEC filing
“Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK, Sarepta, Visirna and Novartis Pharma AG ("Novartis").” SEC filing
“The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement.” SEC filing
“The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement.” SEC filing
“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories.” SEC filing
“License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.” SEC filing
“Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F.” SEC filing
“licensed to GSK and Visirna);” SEC filing
“The change was primarily driven by increased revenue recognition associated with the Sarepta, Sanofi, and GSK license agreements as discussed below.” SEC filing
“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories.” SEC filing
“In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $ 410.0 million in cash to the Company in consideration for the Company's future royalty interest in olpasiran, a siRNA originally developed by the Company...” SEC filing
“Evaluation of distinct performance obligations related to the license and collaboration agreement with Sarepta Therapeutics, Inc” SEC filing
Companies whose annual reports name ARROWHEAD PHARMACEUTICALS, INC. 2
“*3 Partnership with Arrowhead Pharmaceuticals” SEC filing
“Exclusive License and Collaboration Agreement, dated November 25, 2024, between Sarepta Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.